Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome

J Infect. 2010 Jun;60(6):452-7. doi: 10.1016/j.jinf.2010.03.017. Epub 2010 Mar 27.

Abstract

Objectives: A retrospective study on isoniazid-resistant tuberculosis (TB) was conducted in the low-burden country, Denmark (DK). The aim was to describe treatment outcome and transmission and to evaluate a mutation analysis for high- and low-level isoniazid resistance detection.

Methods: In the period 2002-2007, all isoniazid-resistant TB-cases were included. Molecular genotyping was performed by standardized IS6110 restriction fragment length polymorphism (RFLP). Identical isoniazid-resistant genotypes, indicating ongoing transmission, were identified from the national RFLP database. An analysis of rifampin (rpoB) and high- or low-level (katG, inhA) isoniazid resistance mutations was performed on subcultured strains.

Results: There were 1825 culture-confirmed cases, of which 111 (6.1%) had monoresistance or polyresistance to isoniazid. Successful short- and long-term treatment outcome was achieved in 80% and 95%, respectively. Overall, the mutation analysis predicted 94% of isoniazid resistance in 111 strains. The katG S315T1 and inhA C15T1 mutations correctly identified high- and low-level isoniazid resistance in 84% and 84% of the strains, respectively.

Conclusions: Isoniazid-resistant TB has a good prognosis in DK. High- and low- level isoniazid resistance does not affect treatment outcome of standard modified treatment. Rapid mutation detection identified the majority of isoniazid-resistant cases however the impact on treatment outcome remains to be determined.

MeSH terms

  • Adult
  • Antibiotics, Antitubercular / pharmacology*
  • Antibiotics, Antitubercular / therapeutic use
  • Denmark / epidemiology
  • Drug Resistance, Bacterial
  • Female
  • Humans
  • Isoniazid / pharmacology*
  • Isoniazid / therapeutic use
  • Male
  • Mutation
  • Mycobacterium tuberculosis / drug effects*
  • Polymorphism, Restriction Fragment Length
  • Retrospective Studies
  • Rifampin / pharmacology
  • Rifampin / therapeutic use
  • Treatment Outcome
  • Tuberculosis / drug therapy*
  • Tuberculosis / epidemiology
  • Tuberculosis / transmission

Substances

  • Antibiotics, Antitubercular
  • Isoniazid
  • Rifampin